Ignite Creation Date:
2024-05-05 @ 6:47 PM
Last Modification Date:
2024-10-26 @ 9:37 AM
Study NCT ID:
NCT00546260
Status:
TERMINATED
Last Update Posted:
2023-08-16
First Post:
2007-10-16
Brief Title:
Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI
Sponsor:
Portola Pharmaceuticals
Organization:
Alexion Pharmaceuticals Inc
Study Overview
Official Title:
Randomized Trial to Evaluate Effect of Adjunctive Antiplatelet Therapy With Intravenous PRT060128 a Selective P2Y12-Receptor Inhibitor Before Primary Percutaneous Intervention PCI in ST-Elevation Myocardial Infarction STEMI Patients
Status:
TERMINATED
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Administrative reasons
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ERASE-MI
Brief Summary:
Safety and efficacy of adjunctive antiplatelet therapy prior to primary percutaneous intervention PCI in patients with ST-Elevation Myocardial Infarction STEMI
Detailed Description:
Patients with STEMI who are to undergo primary PCI will be randomized to an intravenous iv bolus of placebo vs PRT060128 prior to angiography
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None